Clinical trial NCT04379310: Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)
Official title: Evaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia: A Single Center Experience in Turkey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid-19
Keywords: covid-19 pneumonia
medication
comorbidity
Lead sponsor: Istanbul Nisantasi University
Sponsor class: OTHER
First posted: 2020-05-07
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: first diagnosis with covid-19 pneumonia

Brief summary: Investigators will recruit patients diagnosed with COVID-19 pneumonia between March 11th, 2020 and April 15th, 2020 in emergency, internal medicine and cardiology outpatient clinics, retrospectively and analyze their clinical and demographic features on admission in regard to their medications used for chronic diseases regularly.

Detailed description: Covid-19 infections demonstrated a pandemic spread after January 2020 and their associations with patient characteristics and comorbidities are intensely studied. Investigators also want to find out potential relations between major medications taken for chronic diseases and clinical parameters of patients with Covid-19 pneumonia.

For the study, investigators will recruit patients diagnosed with COVID-19 pneumonia between March 11th, 2020 (the date at which the first case of Covid-19 in Turkey officially declared) and April 15th, 2020 in emergency, internal medicine and cardiology outpatient clinics, retrospectively. All of the demographic features, complaints on admission, reports of computed tomography (CT) scans of the chest without intravenous contrast issued by the staff radiologist, c-reactive protein (CRP) and complete blood count (CBC) values on admission will be recorded retrospectively. Their polymerase chain reaction (PCR) test results will be derived from the hospital records based on public health covid-19 database notifications and list of medications taken regularly for more than 8 weeks before the diagnosis of COVID-19 pneumonia from the national pharmacy database. Information about other systemic diseases and major medical conditions of patients will be procured from the medical histories gained by relevant physicians. Patient taking each drug group will be compared to those not taking that drugs in terms of clinical and demographical features mentioned above. Statistical analysis will be performed by using SPSS software.

Eligibility criteria: Inclusion Criteria:

* Covid-19 pneumonia at least with typical infiltration on CT +/- positive PCR.

Exclusion Criteria:

* no typical infiltration and negative PCR results.
* not newly diagnosed.

Primary outcomes:
measure: extend of lung involvement
timeFrame: 1 week
measure: oxygen saturation on admission
timeFrame: 2 week
Secondary outcomes:
Other outcomes:
Locations:
city: Bahcelievler
country: Turkey
facility: Vital Hospital
state: Istanbul
Study officials:
affiliation: academic staff, MD
name: Hasan Haciosman
role: STUDY_CHAIR
References: